Redeye views AroCell’s management transition as a sound solution to Michael Brobjer’s resignation, appointing CFO Anders Hultman as the new CEO. We emphasize Anders Hultman working closely alongside the CEO since they joined the company in late 2018 and argue that this will mitigate the risk of disturbance related to its commercialization. Moreover, Michael Brobjer will remain a consultant during the US launch phase, which we expect to accelerate towards the second half of 2021. The coming eventual FDA approval, which fully enables commercialization, is the most critical catalyst for the share which is currently leaving a 130% potential to our Base Case of SEK 5 per share.
Oscar Bergman
Equity Analyst
Tagged companies
You need to be a Redeye member to access this content
Become a member to:
Access all our extensive research on 100+ Nordic Tech and Life Science companies
Make smarter investment decisions with the guidance of our experienced analysts
Receive exciting offers to participate in IPO’s and other transactions
By clicking "Sign up" you indicate that you read and agree to our Terms & Conditions
